Most Recent Articles by Deborah Weinstein
Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.
The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.
The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
Philadelphia Transportation Authority sues Gilead over Sovaldi sticker shock; Digital marketing tactics raise privacy concerns; another patent cliff is on the horizon.
More Articles by Deborah Weinstein
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.